Shinsuke Ogusu

Discontinuation due to immune‐related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non‐small cell lung cancer

Kazutoshi Komiya, Tomomi Nakamura, Tomonori Abe et al. · Thoracic Cancer · 2019 · 59 citations · Full text

Medicine, Oncology, Pharmacology +16

Feasibility of next‐generation sequencing test for patients with advanced <scp>NSCLC</scp> in clinical practice

Ryo Ariyasu, Ken Uchibori, Hironori Ninomiya et al. · Thoracic Cancer · 2020 · 29 citations · Full text

Medicine, Molecular Medicine, Oncology +14

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer

Siew‐Kee Low, Ryo Ariyasu, Ken Uchibori et al. · Translational Lung Cancer Research · 2022 · 28 citations · Full text

Medicine, Molecular Biology, Oncology +17

Impact of Renin–angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients

Takehiro Tozuka, Noriko Yanagitani, Hiroshi Yoshida et al. · Anticancer Research · 2021 · 19 citations · Full text

Medicine, Oncology, Pharmacology +17

Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy

Kazutoshi Komiya, Chiho Nakashima, Tomomi Nakamura et al. · Anticancer Research · 2018 · 16 citations · Full text

Medicine, Molecular Medicine, Oncology +17